Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $176.94 Analyst target: $202.22 Upside: 14.29%
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.